Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson’s disease to clinical trials
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy
Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy
Accure Therapeutics appoints Dr Philippe Monteyne as Chairman of the Board of Directors
L’agencia per a la Competitivitat de l’Empresa, ACCIÓ, en data 1 de març de 2018 ha atorgat a Iproteos (Accure Therapeutics) la concessió d’una subvenció per les seves aportacions a les teràpies pel Parkinson
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics
Conferencia online: “La esclerosis múltiple en los próximos 15 años”
Webinars on Neuroprotection for Brain Diseases Program
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy
